此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Phase 1 Study of QLS7402 Injection in Adult Participants With Overweight or Obesity

A Randomized, Double-blind, Placebo-controlled Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Dose of QLS7402 Injection Administered Subcutaneously in Adult Participants With Overweight or Obesity

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending dose of QLS7402 injection administered subcutaneously in adult participants with overweight or obesity

研究概览

详细说明

This is a first-in-human (FIH), randomized, double-blind, placebo-controlled Phase 1 clinical study of QLS7402 injection, which consists of a single ascending dose (SAD) study in adult participants with overweight or obesity. The study is designed to evaluate the safety, tolerability, PK, and PD of QLS7402 following single subcutaneous administration. In accordance with the dose escalation principle, dose escalation will proceed sequentially from the starting dose to higher dose levels. An individual trial participant will receive only one dose level as a single dose. This study is designed with 5 prespecified escalating dose groups.

研究类型

介入性

注册 (估计的)

40

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Qing wen, Master of Medicine
  • 电话号码:+86-13370551767
  • 邮箱:wenq0619@126.com

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 55年 (成人)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • 1)Willing to participate in this study and provide written informed consent prior to any study-specific procedures; able to understand the study procedures, methods, requirements, and restrictions; and willing to comply with the protocol and complete the study.
  • 2) Male and female adults aged between 18 and 55 years, inclusive, at the time of informed consent.
  • 3) 27.0 kg/m²≤BMI<35.0 kg/m² at screening.
  • 4) Body weight has remained stable for at least 3 months prior to screening(defined as a weight change within ±5%, participant self-reported information is acceptable).

Exclusion Criteria:

  • 1) Evidence or history or presence of major diseases, including but not limited to disorders involving the cardiovascular, endocrine (except for primary obesity and mild to moderate hepatic steatosis with normal hepatic function), psychiatric, neurological, gastrointestinal, respiratory, hematological, immunological, urogenital, renal, hepatic, pulmonary, or dermatological systems, or any other condition that, in the judgment of the Investigator, makes the participant unsuitable for this study.
  • 2) History of endocrine disorders that may significantly affect body weight (e.g., Cushing's syndrome, hypothalamic obesity, hypothyroidism, or hyperthyroidism), or history of medication-induced obesity, monogenic obesity, or hereditary obesity syndromes.
  • 3) History of malignancy.
  • 4) Skin conditions and/or tattoos that may interfere with the evaluation of injection site reactions, or abdominal scarring (e.g., due to surgery or burns) that may affect subcutaneous administration; intolerance to subcutaneous injection which, in the investigator's opinion, may preclude study drug administration or local tolerability assessment.
  • 5) Difficult venous access (e.g., history of needle phobia or blood phobia), or poor venous conditions that, in the judgment of the Investigator, render the participant unsuitable for enrollment.
  • 6) History of or planned any form of bariatric surgery or device-based treatment for obesity during the study period; severe trauma or major surgery within 6 months prior to screening; or planned surgery during the study period.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:QLS7402

QLS7402 Injection

QLS7402 Injection

安慰剂比较:Placebo

Placebo Control

Placebo Control

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Number of participants with treatment-emergent adverse events (TEAEs)
大体时间:169 days
169 days
Number of participants with treatment-related adverse events (TRAEs)
大体时间:169 days
169 days
Number of participants with serious adverse events (SAEs)
大体时间:169 days
169 days
Number of participants with abnormal physical examination, 12-lead ECG and clinical laboratory tests
大体时间:169 days
169 days

次要结果测量

结果测量
大体时间
The change from baseline in Maximum Plasma Concentration (Cmax)
大体时间:3 days
3 days
The change from baseline in Activin E levels
大体时间:169 days
169 days

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2027年1月13日

初级完成 (估计的)

2027年10月29日

研究完成 (估计的)

2028年4月30日

研究注册日期

首次提交

2026年11月10日

首先提交符合 QC 标准的

2026年11月15日

首次发布 (实际的)

2026年11月20日

研究记录更新

最后更新发布 (实际的)

2026年11月20日

上次提交的符合 QC 标准的更新

2026年11月15日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅